Trial intelligence / Profile preview

Pyxis: Brexpiprazole Adjunctive Therapy in MDD

NCT01360645Phase 3Completed

Sponsor
Otsuka Pharmaceutical Development & Commercialization
Start
Jul 2011
Primary completion
May 2013
Modality
Small Molecules
Countries
5
01

Overview

A Phase 3 trial of brexpiprazole orally disintegrating tablet in major depressive disorder (MDD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Started Jul 2011; status: completed.

02

Drugs

brexpiprazole orally disintegrating tablet
03

Conditions

major depressive disorder (MDD)

Beyond the preview

Go deeper on NCT01360645.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01360645.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call